Ambroxol inhalation for mucus clearance in palliative care patients - a randomized placebo-controlled double-blind pilot study.

Phase 1

• Conditions: cancer; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2020-004377-44-AT
• Lead Sponsor: Med. Univ. Wien, Innere Med. I, Abt. f. Palliativmedizin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-07-13
• Last Update Posted: 16 May 2022

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Patients over 18 years of age,
- No pregnancy
- History of more than three sputum sputum sputum sputum sputum sputum sputum sputum sputum sputum sputum per day,
- No mucolytic medication
- No reasons for non-participation (e.g., cognitive deficit, delirium, marked dementia or severe psychiatric illness, excessively poor performance status, severe septicemia with impaired consciousness, intolerance of ABX)
- No language barrier
- Given ability to sign verbal as well as written informed consent.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 10
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10

Exclusion Criteria

none

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified